Incyte Corporation (INCY) Discusses mutCALR Data and Therapeutic Advances in Myeloproliferative Neoplasms at ASH December 7, 2025 11:00 AM EST
Company Participants
Pablo Cagnoni - President and Head of Research & Development Steven Stein - Executive VP & Chief Medical Officer
Conference Call Participants
Claire Harrison John Mascarenhas Bethan Psaila Brian Abrahams - RBC Capital Markets, Research Division Erik Lavington - Mizuho Securities USA LLC, Research Division Michael Schmidt - Guggenheim Securities, LLC, Research Division Srikripa Devarakonda - Truist Securities, Inc., Research Division Tazeen Ahmad - BofA Securities, Research…
Incyte Corporation (INCY) Discusses mutCALR Data and Therapeutic Advances in Myeloproliferative Neoplasms at ASH December 7, 2025 11:00 AM EST
Company Participants
Pablo Cagnoni - President and Head of Research & Development Steven Stein - Executive VP & Chief Medical Officer
Conference Call Participants
Claire Harrison John Mascarenhas Bethan Psaila Brian Abrahams - RBC Capital Markets, Research Division Erik Lavington - Mizuho Securities USA LLC, Research Division Michael Schmidt - Guggenheim Securities, LLC, Research Division Srikripa Devarakonda - Truist Securities, Inc., Research Division Tazeen Ahmad - BofA Securities, Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Marc Frahm - TD Cowen, Research Division Ashwani Verma - UBS Investment Bank, Research Division James Shin - Deutsche Bank AG, Research Division Reni Benjamin - Citizens JMP Securities, LLC, Research Division Etzer Darout - Barclays Bank PLC, Research Division Matthew Phipps - William Blair & Company L.L.C., Research Division Imogen Mansfield - Cantor Fitzgerald & Co., Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division
Presentation
Pablo Cagnoni President and Head of Research & Development
Okay. Good morning, everyone, and welcome. Welcome those of you here at – in Orlando at ASH, and welcome those at the webcast. Apologies for the late start. We had to adhere to certain guidelines from ASH, and there was no way to schedule this. And 2 of our speakers were busy presenting actually scientific data at the meeting. So we were forced to start a little bit late. So thank you for your patience. I’m sure you had an opportunity to grab some lunch. We’re going to spend the next 45 minutes or so reviewing data from our 989. We’re going to call it 989 for short program with you. I think this data, some of it was presented in June of this year at AHA in patients with ET. And yesterday and today, you heard from 2 of our speakers today about the translational data and the data in MF. We think this is a really important